PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
NCT #
4995198
Condition(s)
Prostate
Molecular Target(s)
N/A
Drug Classification(s)
n/a
Agents(s)
N/A
Phase(s)
N/A
Mechanism of Action
N/A
Purpose
The purpose of this research is to identify people with prostate cancer who have certain genetic mutations. Researchers know that some genetic mutations can lead to prostate cancer, or make prostate cancer worse. This study will seek to understand these mutations better.
- Have prostate cancer (any stage of disease or survivorship) diagnosed or documented through one of the following:
- tissue biopsy, and/or
- PSA greater than 100 ng/dL (1ng/ml), and/or
- clear radiographic evidence of disease
- Live in the United States (including Puerto Rico, Guam, American Samoa, US Virgin Islands, Northern Mariana Islands)
- Unable or unwilling to provide all of the necessary information for eligibility
- Incomplete inclusion criteria
No restrictions
Location
UCNT
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
UC23-03
N/A
n/a
N/A
Prostate
UCNT
UC23-02
Potent, highly selective, allosteric, orally bioavailable, small molecule inhibitor ofPRC2 via binding the embryonic ectoderm development (EED) subunit
Small Molecule
Not Required
Prostate
UCNT
22-42
ALG.APV-527 binds to both its targets, 4-1BB and 5T4. ALG.APV-527 has the potential to activate T cells and NK cells that are present in the...
Bispecific Antibodies
Not required
Breast, Cervical, Colorectal, Endometrial, Gastric/Gastro-Esophageal, head and neck squamous cell carcinoma, Mesothelioma, Non-Small Cell Lung, Ovarian, Pancreatic, Prostate, Renal cell, urothelial carcinoma
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.